Spotlight on Allergy & Immunology
Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Allergy & Immunology Presentations

Expert Perspectives on Current and Emerging Therapies in Chronic Spontaneous Urticaria
StartActivity Details
Expires: September 21, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
- Examine the role of biomarkers and their implications in CSU management.
- Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.
Activity Description
In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.
Agenda
Chronic Spontaneous Urticaria: Burden, Clinical Implications of
Biomarkers
Kristin Sokol, MD, MPH, MS
CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD
CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Activity Chair

Professor of Medicine
The Medical University of South Carolina
Charleston, SC
Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis
Faculty

Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL
Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD
Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Disclaimer Statement
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Notice
Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.
Contact Information for Questions About the Activity
CME Questions?
Contact us
at cme@vindicoCME.com
Activity Details
Expires: September 21, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
- Examine the role of biomarkers and their implications in CSU management.
- Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.
Activity Description
In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.
Agenda
Chronic Spontaneous Urticaria: Burden, Clinical Implications of
Biomarkers
Kristin Sokol, MD, MPH, MS
CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD
CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Activity Chair

Professor of Medicine
The Medical University of South Carolina
Charleston, SC
Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis
Faculty

Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL
Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD
Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Disclaimer Statement
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Notice
Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.
Contact Information for Questions About the Activity
CME Questions?
Contact us
at cme@vindicoCME.com

Challenging Cases in Asthma: Optimizing Biologics in Adults
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Challenging Cases in Asthma: Improving Quality of Life
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.